Dihydroergotamine Nasal Spray

157 interactions 472 cited references

Also sold as: Migranal Migranal® Nasal Spray Trudhesa Trudhesa® Nasal Spray

About Dihydroergotamine Nasal Spray

Dihydroergotamine is used to treat migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Dihydroergotamine is in a class of medications called ergot alkaloids. It works by tightening blood vessels in the brain and by stopping the release of natural… Read the full Dihydroergotamine Nasal Spray drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Troleandomycin Adagrasib Tucatinib Almotriptan Zolmitriptan Vasopressin

62 Contraindicated 79 Major 16 Moderate

All (157) Contraindicated (62) Major (79) Moderate (16)

Major

Dihydroergotamine Nasal Spray Ranolazine Aspruzyo Increased exposure of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Dihydroergotamine Nasal Spray Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Dihydroergotamine Nasal Spray Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Dihydroergotamine Nasal Spray Schizandra Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Dihydroergotamine Nasal Spray Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Dihydroergotamine Nasal Spray Sibutramine An increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes) Details Dihydroergotamine Nasal Spray Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Dihydroergotamine Nasal Spray Stiripentol Diacomit Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Suzetrigine Journavx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Nasal Spray Taurursodiol Decreased exposure of the CYP3A4 substrate Details Dihydroergotamine Nasal Spray Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Nasal Spray Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Dihydroergotamine Nasal Spray Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Nasal Spray Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Dihydroergotamine Nasal Spray Verapamil Calan Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Vonoprazan Voquezna Increased CYP3A substrates exposure Details Dihydroergotamine Nasal Spray Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Dihydroergotamine Nasal Spray Voxelotor Oxbryta Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Zileuton Zyflo Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details

Moderate

Dihydroergotamine Nasal Spray Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Citalopram Celexa An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Nasal Spray Escitalopram Lexapro An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Nasal Spray Infliximab Avsola Decreased dihydroergotamine plasma concentrations Details Dihydroergotamine Nasal Spray Kratom Increased CYP3A substrate exposure Details Dihydroergotamine Nasal Spray Lapatinib Tykerb Increased exposure of dihydroergotamine Details Dihydroergotamine Nasal Spray Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Metreleptin Altered exposure to dihydroergotamine Details Dihydroergotamine Nasal Spray Metronidazole Flagyl Increased plasma concentrations of ergot derivatives and increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Nitroglycerin Gonitro Dihydroergotamine toxicity (peripheral ischemia, paresthesias, nausea, vomiting) Details Dihydroergotamine Nasal Spray Paroxetine Paxil An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Nasal Spray Rilonacept Altered dihydroergotamine plasma concentrations Details Dihydroergotamine Nasal Spray Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Dihydroergotamine Nasal Spray Sertraline An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Nasal Spray Vilazodone Viibryd An increased risk of weakness, hyperreflexia and incoordination Details Dihydroergotamine Nasal Spray Vortioxetine Trintellix An increased risk of weakness, hyperreflexia and incoordination Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.